Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 770

1.

Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study - 2012 - 2015.

Raben D, Sullivan AK, Mocroft A, Kutsyna G, Hadžiosmanović V, Vassilenko A, Chkhartisvili N, Mitsura V, Pedersen C, Anderson J, Begovac J, Bak Dragsted U, Bertisch B, Grzeszczuk A, Minton J, Necsoi VC, Kitchen M, Ajana F, Sokhan A, Comi L, Farazmand P, Pesut D, De Wit S, Gatell JM, Gazzard B, d'Arminio Monforte A, Rockstroh JK, Yazdanpanah Y, Champenois K, Jakobsen ML, Lundgren JD; HIDES Study Group.

PLoS One. 2019 Aug 13;14(8):e0220108. doi: 10.1371/journal.pone.0220108. eCollection 2019.

2.

Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus-associated cardiovascular risk.

Taylor KA, Smyth E, Rauzi F, Cerrone M, Khawaja AA, Gazzard B, Nelson M, Boffito M, Emerson M.

Br J Pharmacol. 2019 Apr;176(7):879-889. doi: 10.1111/bph.14589. Epub 2019 Mar 14.

PMID:
30681136
3.

Correction to: CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.

Barber TJ, Imaz A, Boffito M, Niubó J, Pozniak A, Fortuny R, Alonso J, Davies N, Mandalia S, Podzamczer D, Gazzard B.

J Neurovirol. 2018 Jun;24(3):388-389. doi: 10.1007/s13365-017-0613-1.

PMID:
29318452
4.

Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy.

Mwasakifwa GE, Moore C, Carey D, Amin J, Penteado P, Losso M, Lim PL, Mohapi L, Molina JM, Gazzard B, Cooper DA, Boyd M; SECOND-LINE Study Group.

AIDS. 2018 Jan 28;32(3):357-361. doi: 10.1097/QAD.0000000000001688. Erratum in: AIDS. 2018 Mar 13;32(5):683.

PMID:
29309346
5.

CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.

Barber TJ, Imaz A, Boffito M, Niubó J, Pozniak A, Fortuny R, Alonso J, Davies N, Mandalia S, Podzamczer D, Gazzard B.

J Neurovirol. 2018 Feb;24(1):98-105. doi: 10.1007/s13365-017-0600-6. Epub 2017 Dec 26. Erratum in: J Neurovirol. 2018 Jan 9;:.

PMID:
29280108
6.

Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial.

Baker JV, Sharma S, Achhra AC, Bernardino JI, Bogner JR, Duprez D, Emery S, Gazzard B, Gordin J, Grandits G, Phillips AN, Schwarze S, Soliman EZ, Spector SA, Tambussi G, Lundgren J; INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) START (Strategic Timing of Antiretroviral Treatment) Study Group.

J Am Heart Assoc. 2017 May 22;6(5). pii: e004987. doi: 10.1161/JAHA.116.004987.

7.

First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.

Nyombayire J, Anzala O, Gazzard B, Karita E, Bergin P, Hayes P, Kopycinski J, Omosa-Manyonyi G, Jackson A, Bizimana J, Farah B, Sayeed E, Parks CL, Inoue M, Hironaka T, Hara H, Shu T, Matano T, Dally L, Barin B, Park H, Gilmour J, Lombardo A, Excler JL, Fast P, Laufer DS, Cox JH; S001 Study Team.

J Infect Dis. 2017 Jan 1;215(1):95-104. doi: 10.1093/infdis/jiw500. Epub 2016 Oct 17.

8.

Low levels of neurocognitive impairment detected in screening HIV-infected men who have sex with men: The MSM Neurocog Study.

Barber TJ, Bansi L, Pozniak A, Asboe D, Nelson M, Moyle G, Davies N, Margetts A, Ratcliffe D, Catalan J, Boffito M, Gazzard B.

Int J STD AIDS. 2017 Jun;28(7):715-722. doi: 10.1177/0956462416665061. Epub 2016 Aug 10.

PMID:
27510645
9.

Editorial.

Gazzard B.

HIV Med. 2016 May;17 Suppl 2:3. doi: 10.1111/hiv.12405. No abstract available.

10.

Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study.

Raben D, Mocroft A, Rayment M, Mitsura VM, Hadziosmanovic V, Sthoeger ZM, Palfreeman A, Morris S, Kutsyna G, Vassilenko A, Minton J, Necsoi C, Estrada VP, Grzeszczuk A, Johansson VS, Begovac J, Ong EL, Cabié A, Ajana F, Celesia BM, Maltez F, Kitchen M, Comi L, Dragsted UB, Clumeck N, Gatell J, Gazzard B, d'Arminio Monforte A, Rockstroh J, Yazdanpanah Y, Champenois K, Jakobsen ML, Sullivan A, Lundgren JD; HIDES Audit Study Group.

PLoS One. 2015 Nov 11;10(11):e0140845. doi: 10.1371/journal.pone.0140845. eCollection 2015.

11.

Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, Sullivan AK, Clarke A, Reeves I, Schembri G, Mackie N, Bowman C, Lacey CJ, Apea V, Brady M, Fox J, Taylor S, Antonucci S, Khoo SH, Rooney J, Nardone A, Fisher M, McOwan A, Phillips AN, Johnson AM, Gazzard B, Gill ON.

Lancet. 2016 Jan 2;387(10013):53-60. doi: 10.1016/S0140-6736(15)00056-2. Epub 2015 Sep 9.

12.

BASHH/EAGA position statement on the HIV window period.

Webster DP, Donati M, Geretti AM, Waters LJ, Gazzard B, Radcliffe K.

Int J STD AIDS. 2015 Sep;26(10):760-1. doi: 10.1177/0956462415579591. No abstract available.

PMID:
26232737
13.

Clinical and demographic factors associated with low viral load in early untreated HIV infection in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Law MG, Achhra A, Deeks SG, Gazzard B, Migueles SA, Novak RM, Ristola M; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group.

HIV Med. 2015 Apr;16 Suppl 1:37-45. doi: 10.1111/hiv.12232.

14.

Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 years.

Gazzard B, Girard PM, Di Perri G, Gallant J, Towner W, Rogatto F, Demorin J, McColl D, Liu H, Rhee M, Szwarcberg J, Piontkowsky D.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19767. doi: 10.7448/IAS.17.4.19767. eCollection 2014.

15.

Patient preferences for characteristics of antiretroviral therapies: results from five European countries.

Gazzard B, Ali S, Muhlbacher A, Ghafouri N, Maggiolo F, Golics C, Nozza S, Fuster MJ, Antela A, Parienti JJ, Dang N, Bregigeon SR, Benzie A, Murray M.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19540. doi: 10.7448/IAS.17.4.19540. eCollection 2014.

16.

30 years of HIV: what have we learned?

Gazzard B.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19478. doi: 10.7448/IAS.17.4.19478. eCollection 2014.

17.

Loss of Th22 cells is associated with increased immune activation and IDO-1 activity in HIV-1 infection.

Page EE, Greathead L, Metcalf R, Clark SA, Hart M, Fuchs D, Pantelidis P, Gotch F, Pozniak A, Nelson M, Boasso A, Gazzard B, Kelleher P.

J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):227-35. doi: 10.1097/QAI.0000000000000294.

PMID:
25314246
18.

Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy.

Waters L, Jackson A, Else L, Rockwood N, Newell S, Back D, Nelson M, Gazzard B, Boffito M.

Antivir Ther. 2015;20(2):157-63. doi: 10.3851/IMP2817. Epub 2014 Jun 25.

PMID:
24963558
19.

CD8+/CD161++ mucosal-associated invariant T-cell levels in the colon are restored on long-term antiretroviral therapy and correlate with CD8+ T-cell immune activation.

Greathead L, Metcalf R, Gazzard B, Gotch F, Steel A, Kelleher P.

AIDS. 2014 Jul 17;28(11):1690-2. doi: 10.1097/QAD.0000000000000351.

PMID:
24911351
20.

A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis.

Jackson AG, Else LJ, Mesquita PM, Egan D, Back DJ, Karolia Z, Ringner-Nackter L, Higgs CJ, Herold BC, Gazzard BG, Boffito M.

Clin Pharmacol Ther. 2014 Sep;96(3):314-23. doi: 10.1038/clpt.2014.118. Epub 2014 May 26.

PMID:
24862215
21.

Assessing the role of peripheral CD8 T cells in neurocognitive impairment in HIV-infected men who have sex with men: data from the MSM Neurocog Study.

Rawson TM, Dubb S, Pozniak A, Kelleher WP, Mandalia S, Gazzard B, Barber TJ.

Int J STD AIDS. 2015 Feb;26(2):128-32. doi: 10.1177/0956462414531934. Epub 2014 Apr 22.

PMID:
24759562
22.

A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy.

Revell AD, Boyd MA, Wang D, Emery S, Gazzard B, Reiss P, van Sighem AI, Montaner JS, Lane HC, Larder BA.

HIV Med. 2014 Aug;15(7):442-8. doi: 10.1111/hiv.12156. Epub 2014 Apr 15.

23.

Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.

Palella FJ Jr, Fisher M, Tebas P, Gazzard B, Ruane P, Van Lunzen J, Shamblaw D, Flamm J, Ebrahimi R, Porter D, White K, Hindman J, Elbert E, De-Oertel S, Fralich T.

AIDS. 2014 Jan 28;28(3):335-44. doi: 10.1097/QAD.0000000000000087. Erratum in: AIDS. 2014 Aug 24;28(13):1999-2001.

PMID:
24670520
24.

HIV-related neurocognitive impairment screening: the patient's perspective on its utility and psychological impact.

Nightingale A, Ratcliffe D, Leonidou L, Margetts A, Asboe D, Gazzard B, Catalan J, Barber TJ.

AIDS Care. 2014;26(8):1036-41. doi: 10.1080/09540121.2014.894619. Epub 2014 Mar 13.

PMID:
24625218
25.

The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era.

Mocroft A, Furrer HJ, Miro JM, Reiss P, Mussini C, Kirk O, Abgrall S, Ayayi S, Bartmeyer B, Braun D, Castagna A, d'Arminio Monforte A, Gazzard B, Gutierrez F, Hurtado I, Jansen K, Meyer L, Muñoz P, Obel N, Soler-Palacin P, Papadopoulos A, Raffi F, Ramos JT, Rockstroh JK, Salmon D, Torti C, Warszawski J, de Wit S, Zangerle R, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Lundgren JD; Opportunistic Infections Working Group on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCOORD.

Clin Infect Dis. 2013 Oct;57(7):1038-47. doi: 10.1093/cid/cit423. Epub 2013 Aug 6.

26.

Screening for HIV-related neurocognitive impairment in clinical practice: challenges and opportunities.

Barber TJ, Bradshaw D, Hughes D, Leonidou L, Margetts A, Ratcliffe D, Thornton S, Pozniak A, Asboe D, Mandalia S, Boffito M, Davies N, Gazzard B, Catalan J.

AIDS Care. 2014 Feb;26(2):160-8. doi: 10.1080/09540121.2013.819401. Epub 2013 Jul 22. Review.

PMID:
23869661
27.

Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM.

Martin TC, Martin NK, Hickman M, Vickerman P, Page EE, Everett R, Gazzard BG, Nelson M.

AIDS. 2013 Oct 23;27(16):2551-7. doi: 10.1097/QAD.0b013e32836381cc.

PMID:
23736152
28.

Comparison of two cohorts of patients presenting with AIDS: patients with previously known HIV diagnoses and true late presenters.

Lee M, Rayment M, Scourfield A, Gazzard B.

Sex Transm Infect. 2013 Nov;89(7):553-6. doi: 10.1136/sextrans-2012-050966. Epub 2013 May 22.

PMID:
23698511
29.

Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics.

Moyle G, Else L, Jackson A, Back D, Yapa MH, Seymour N, Ringner-Nackter L, Karolia Z, Gazzard B, Boffito M.

Antimicrob Agents Chemother. 2013 Aug;57(8):3640-4. doi: 10.1128/AAC.00357-13. Epub 2013 May 20.

30.

Controlling the HIV epidemic with antiretrovirals: IAPAC consensus statement on treatment as prevention and preexposure prophylaxis.

Mayer K, Gazzard B, Zuniga JM, Amico KR, Anderson J, Azad Y, Cairns G, Dedes N, Duncombe C, Fidler SJ, Granich R, Horberg MA, McCormack S, Montaner JS, Rees H, Schackman B, Sow PS; International Association of Physicians in AIDS Care.

J Int Assoc Provid AIDS Care. 2013 May-Jun;12(3):208-16. doi: 10.1177/2325957413475839.

PMID:
23666450
31.

The immunomodulatory nutritional intervention NR100157 reduced CD4+ T-cell decline and immune activation: a 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study).

Cahn P, Ruxrungtham K, Gazzard B, Diaz RS, Gori A, Kotler DP, Vriesema A, Georgiou NA, Garssen J, Clerici M, Lange JM; (BTE) Blinded Nutritional Study for Immunity and Tolerance Evaluation Study Team.

Clin Infect Dis. 2013 Jul;57(1):139-46. doi: 10.1093/cid/cit171. Epub 2013 Mar 19.

32.

Position statement on the use of antiretroviral therapy to reduce HIV transmission, January 2013: the British HIV Association (BHIVA) and the Expert Advisory Group on AIDS (EAGA).

Fidler S, Anderson J, Azad Y, Delpech V, Evans C, Fisher M, Gazzard B, Gill N, Lazarus L, Lowbury R, Orton K, Osoro B, Radcliffe K, Smith B, Churchill D, Rogstad K, Cairns G.

HIV Med. 2013 May;14(5):259-62. doi: 10.1111/hiv.12025. Epub 2013 Mar 12. No abstract available.

33.

Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.

Winston A, Jose S, Gibbons S, Back D, Stohr W, Post F, Fisher M, Gazzard B, Nelson M, Gilson R, Orkin C, Johnson M, Palfreeman A, Chadwick D, Leen C, Schwenk A, Anderson J, Gompels M, Dunn D, Khoo S, Sabin C; UK Collaborative HIV Cohort Study.

J Antimicrob Chemother. 2013 Jun;68(6):1354-9. doi: 10.1093/jac/dkt029. Epub 2013 Feb 23.

PMID:
23435690
34.

Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.

Hayes P, Gilmour J, von Lieven A, Gill D, Clark L, Kopycinski J, Cheeseman H, Chung A, Alter G, Dally L, Zachariah D, Lombardo A, Ackland J, Sayeed E, Jackson A, Boffito M, Gazzard B, Fast PE, Cox JH, Laufer D.

Clin Vaccine Immunol. 2013 Mar;20(3):397-408. doi: 10.1128/CVI.00637-12. Epub 2013 Jan 23.

35.

Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study).

Sullivan AK, Raben D, Reekie J, Rayment M, Mocroft A, Esser S, Leon A, Begovac J, Brinkman K, Zangerle R, Grzeszczuk A, Vassilenko A, Hadziosmanovic V, Krasnov M, Sönnerborg A, Clumeck N, Gatell J, Gazzard B, Monforte Ad, Rockstroh J, Lundgren JD.

PLoS One. 2013;8(1):e52845. doi: 10.1371/journal.pone.0052845. Epub 2013 Jan 15.

36.

Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.

Jackson A, Moyle G, Watson V, Tjia J, Ammara A, Back D, Mohabeer M, Gazzard B, Boffito M.

J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):275-81. doi: 10.1097/QAI.0b013e3182829bd0.

PMID:
23274933
37.

Early and nonreversible decrease of CD161++ /MAIT cells in HIV infection.

Cosgrove C, Ussher JE, Rauch A, Gärtner K, Kurioka A, Hühn MH, Adelmann K, Kang YH, Fergusson JR, Simmonds P, Goulder P, Hansen TH, Fox J, Günthard HF, Khanna N, Powrie F, Steel A, Gazzard B, Phillips RE, Frater J, Uhlig H, Klenerman P.

Blood. 2013 Feb 7;121(6):951-61. doi: 10.1182/blood-2012-06-436436. Epub 2012 Dec 18.

38.

Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.

Beck EJ, Mandalia S, Sangha R, Youle M, Brettle R, Gompels M, Johnson M, Pozniak A, Schwenk A, Taylor S, Walsh J, Wilkins E, Williams I, Gazzard B; NPMS-HHC Steering Group.

PLoS One. 2012;7(10):e47376. doi: 10.1371/journal.pone.0047376. Epub 2012 Oct 30.

39.

Pancreatic insufficiency in patients with HIV infection: role of didanosine questioned.

Martin TC, Scourfield A, Rockwood N, Martin NK, Patel N, Nelson M, Gazzard BG.

HIV Med. 2013 Mar;14(3):161-6. doi: 10.1111/j.1468-1293.2012.01047.x. Epub 2012 Sep 21.

40.

A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience.

Waters L, Patterson B, Scourfield A, Hughes A, de Silva S, Gazzard B, Barton S, Asboe D, Pozniak A, Boffito M.

Int J STD AIDS. 2012 Aug;23(8):546-52. doi: 10.1258/ijsa.2012.011412.

PMID:
22930290
41.

Short communication: NKG2C+ NK cells contribute to increases in CD16+CD56- cells in HIV type 1+ individuals with high plasma viral load.

Gregson JN, Kuri-Cervantes L, Mela CM, Gazzard BG, Bower M, Goodier MR.

AIDS Res Hum Retroviruses. 2013 Jan;29(1):84-8. doi: 10.1089/AID.2011.0397. Epub 2012 Sep 25.

42.

New strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United Kingdom.

Gazzard B, Moecklinghoff C, Hill A.

Clinicoecon Outcomes Res. 2012;4:193-200. doi: 10.2147/CEOR.S12496. Epub 2012 Jul 12.

43.

Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.

Paton NI, Goodall RL, Dunn DT, Franzen S, Collaco-Moraes Y, Gazzard BG, Williams IG, Fisher MJ, Winston A, Fox J, Orkin C, Herieka EA, Ainsworth JG, Post FA, Wansbrough-Jones M, Kelleher P; Hydroxychloroquine Trial Team.

JAMA. 2012 Jul 25;308(4):353-61. doi: 10.1001/jama.2012.6936.

44.

CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE.

Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord, Young J, Psichogiou M, Meyer L, Ayayi S, Grabar S, Raffi F, Reiss P, Gazzard B, Sharland M, Gutierrez F, Obel N, Kirk O, Miro JM, Furrer H, Castagna A, De Wit S, Muñoz J, Kjaer J, Grarup J, Chêne G, Bucher H.

PLoS Med. 2012;9(3):e1001194. doi: 10.1371/journal.pmed.1001194. Epub 2012 Mar 20.

45.

Are long-term non-progressors very slow progressors? Insights from the Chelsea and Westminster HIV cohort, 1988-2010.

Mandalia S, Westrop SJ, Beck EJ, Nelson M, Gazzard BG, Imami N.

PLoS One. 2012;7(2):e29844. doi: 10.1371/journal.pone.0029844. Epub 2012 Feb 20.

47.

Biomarkers to monitor safety in people on art and risk of mortality.

Bansi L, Gazzard B, Post F, Phillips A, Johnson M, Hill T, Gilson R, Leen C, Walsh J, Fisher M, Sabin C; UK Collaborative HIV Cohort Study.

J Acquir Immune Defic Syndr. 2012 May 1;60(1):51-8. doi: 10.1097/QAI.0b013e31824d2134.

PMID:
22330610
48.

Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?

Gompels M, Dunn DT, Phillips A, Dooley D, De Burgh Thomas A, Anderson J, Post F, Pillay D, Gazzard B, Hill T, Johnson M, Gilson R, Bansi L, Easterbrook P, Fisher M, Walsh J, Orkin C, Ainsworth J, Leen C, Sabin C; UK Collaborative HIV Cohort (UK CHIC) Study (Appendix).

J Infect Dis. 2012 Feb 15;205(4):540-7. doi: 10.1093/infdis/jir380.

PMID:
22279171
49.

Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.

Jackson A, Moyle G, Dickinson L, Back D, Khoo S, Taylor J, Gedela K, Abongomera G, Gazzard B, Boffito M.

Antivir Ther. 2012;17(1):19-24. doi: 10.3851/IMP1910.

50.

The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008.

Beck EJ, Mandalia S, Sangha R, Sharott P, Youle M, Baily G, Brettle R, Gompels M, Johnson M, McCarron B, Ong E, Pozniak A, Schwenk A, Taylor S, Walsh J, Wilkins E, Williams I, Gazzard B; NPMS-HHC Steering Group.

PLoS One. 2011;6(12):e27830. doi: 10.1371/journal.pone.0027830. Epub 2011 Dec 14.

Supplemental Content

Loading ...
Support Center